Professor Richard Gilbertson MBBS, PhD
Click here to find out more
This March, for one night only, we're bringing you a unique opportunity to hear from some of the world's leading researchers in the fight against brain tumours.
Including members of our expert Scientific Advisory Board and led by the renowned Professor Richard Gilbertson, the panel of researchers will include Dr Paul Northcott, Professor Martin van den Bent and Dr Colin Watts, who will come together to update you on brand new, innovative research and answer any questions you might have.
So, if you find it hard to wrap your head around the role of genetics, or maybe you'd like to learn more about how new therapies are developed, then this is the event for you! This is an opportunity for anyone who would like to know a bit more about research into brain tumours. The presentations are designed with a public audience in mind, so you don't need to have an in-depth understanding of science or research to enjoy the event and learn something new.
The event will also be hosted by ITV news journalist and OBE, Alastair Stewart, who has a personal connection to The Charity and is a well-respected newscaster with decades of experience.
Professor Richard Gilbertson is one of the world's leading experts in childhood brain tumours. He will kick-start our event by introducing you to the world of brain tumour research.
He is currently the Director of the Cancer Research UK Cambridge Centre at Cambridge University and has been working in paediatric oncology as both a clinician and a researcher for almost 25 years.
His work has helped identify different subtypes of medulloblastoma and ependymoma – two of the most common types of childhood brain tumour. This has been translated into numerous diagnostic tests and innovative clinical trials for children with brain tumours.
Professor Gilbertson's dedication to conducting research to understand more about childhood brain tumours continues to shed light on the differences between the subtypes of medulloblastoma and ependymoma, which is vital to improve the diagnosis and treatment of brain tumours.
Dr Paul Northcott is a leading paediatric cancer genome scientist. On the night, he will talk about research into paediatric brain tumours and the importance of international research collaborations to pool expertise and speed-up breakthroughs.
The Northcott lab is interested in solving the molecular and cellular origins of medulloblastoma (a childhood brain tumour). Combining cutting-edge, next-generation sequencing and integrative computational approaches with in vivo functional studies, they aim to comprehensively understand the genetic, epigenetic, and transcriptional landscapes underlying medulloblastoma.
Dr Northcott's novel and innovative work is helping us understand the role of genetics in tumour development, and bringing us closer to new and better treatments that can slow tumour growth.
Professor Martin van den Bent serves as Head of the Neuro-Oncology Unit of the Daniel den Hoed Cancer Centre at Erasmus University Hospital, The Netherlands. He is a neurologist, specialising in neurological complications of cancer and in primary brain tumours.
Professor van den Bent is the Principle Investigator of numerous phase two and three multi-centre clinical trials on primary brain tumours. His other research interests include prognostic markers in neuro-oncology and genetic changes that occur in brain tumours.
You'll hear him speak on the current state of research into adults brain tumours and talk about the landscape of clinical trials.
Dr Watts specialises in the genomics of glioblastoma (GBM) and in the role of glial progenitors in their evolution and development. He will close our series of presentations by talking about the key developments and commitments that came out of the recent UK Brain Cancer Summit, and what this means for the future of the brain tumour community.